je.st
news
Home
› Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections
Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections
2013-10-30 05:42:32| drugdiscoveryonline News Articles
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate Taksta™ (CEM-102) for the treatment of prosthetic joint infections (PJI)
Tags: treatment
drug
joint
receives
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||